A Comparison between Sequential Therapy and a Modified Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Iran: A Randomized Clinical Trial

Helicobacter

Volumn 17, Issue 1, 2012, Pages 43-48

  Fakheri, Hafez ^a   Taghvaei, Tarang ^a   Hosseini, Vahid ^a   Bari, Zohreh ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clarithromycin; Furazolidone; Helicobacter pylori; Iran

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 14; CLARITHROMYCIN; FURAZOLIDONE; PANTOPRAZOLE; TINIDAZOLE;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIMICROBIAL THERAPY; ARTICLE; BLOATING; BLURRED VISION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DUODENUM ULCER; DYSURIA; ERADICATION THERAPY; FEMALE; FEVER; GLOSSITIS; HALITOSIS; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; IRAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MODIFIED BISMUTH BASED QUADRUPLE THERAPY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEQUENTIAL THERAPY; SHORT COURSE THERAPY; SKIN TINGLING; TASTE DISORDER; THORAX PAIN; TREATMENT DURATION; TREMOR; UREA BREATH TEST; URTICARIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

HELICOBACTER PYLORI;

EID: 84855413819     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00896.x     Document Type: Article

References (42)

1. Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008;13(Suppl 1):35-40.
2. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
3. Nam T, Lee D, Kang K, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc 2008;36:200-5.
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
5. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
6. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline - comparison of three 3-year studies. Arch Iranian Med 2010;13:177-87.
7. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79, quiz 1080.
8. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41-53.
9. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.
10. Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Tito L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008;103:2220-3.
11. Kwon JH, Lee DH, Song BJ, et al. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 2010;15:148-53.
12. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41e1.
13. Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol 2010;105:1071-5.
14. Saberi-Firoozi M, Massarrat S, Zare S, et al. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study. Am J Gastroenterol 1995;90:1419-23.
15. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, et al. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit 2003;9:PI105-8.
16. Daghaghzadeh H, Emami MH, Karimi S, Raeisi M. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran. J Gastroenterol Hepatol 2007;22:1399-403.
17. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
18. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
19. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000;95:2688-91.
20. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
21. Graham DY, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti Helicobacter pylori therapy. Ann Intern Med 2007;147:434-5.
22. Malekzadeh R, Merat S, Derakhshan MH, et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003;18:13-7.
23. Moayyedi P, Malfertheiner P. Editorial: sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol 2009;104:3081-3.
24. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25.
25. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100.
26. Choi WH, Park DI, Oh SJ, et al. [Effectiveness of 10day-sequential therapy for Helicobacter pylori eradication in Korea]. Korean J Gastroenterol 2008;51:280-4.
27. Park S, Chun H, Kim E, et al. The 10-day sequential therapy for Helicobacter pylori eradication in Korea: less effective than expected. Gastroenterology 2009;136:A339-40.
28. Paoluzi OA, Visconti E, Andrei F, et al. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol 2010;44:261-6.
29. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-70.
30. Ruiz-Obaldi′a J, Torrazza E, Carreno N. Helicobacter pylori eradication with either conventional 10-day triple therapy or 10-day modified sequential regimen. Gastroenterology 2008;134:A-24.
31. Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-6.
32. Kwon DH, Lee M, Kim JJ, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001;45:306-8.
33. Felga GE, Silva FM, Barbuti RC, Navarro-Rodriguez T, Zaterka S, Eisig JN. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J Gastroenterol 2008;14:6224-7.
34. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009;15:860-4.
35. Sanches B, Coelho L, Moretzsohn L, Vieira G Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter 2008;13:572-6.
36. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
37. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000;14:211-5.
38. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004;19:89-93.
39. Hasan SR, Vahid V, Reza PM, Roham SR. Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori. Saudi J Gastroenterol 2010;16:14-8.
40. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
41. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997;41:8-13.
42. Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 2010;15:505-9.